Condition: KCNT1-Related Epilepsy · Sponsor: Actio Biosciences, Inc.
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
This description comes directly from the study's public registry record.
Medical Director Actio Biosciences, Inc. · +1 (858) 682-4042 · info@actiobiosciences.com
Always discuss trial participation with your own doctor first.
| Northeast Regional Epilepsy Group | Hackensack, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07600736